Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Approvals of Janssen's daratumumab and Bristol-Myers Squibb's elotuzumab cap a stellar year for multiple myeloma therapies, providing two new mechanisms of action and prompting a slew of combination trials.
Just weeks after an FDA advisory meeting on the use of vaccines in pregnant women to protect newborn babies, Novavax has launched the first ever Phase III trial of a vaccine for maternal immunization licensure.
With biosimilar monoclonal antibodies now entering the market and a surge of biosimilars expected once the patents for major pioneer products expire, this article analyses experiences so far and future market dynamics.
Over the past decade, the drug–target residence time model has been broadly applied to drug discovery programmes across multiple therapeutic areas. To mark the 10 year anniversary of this model, Copeland discusses the benefits of assessing residence time, highlighting some of the advances in its theory and application.
The gasotransmitters nitric oxide, carbon monoxide and hydrogen sulfide are involved in a large number of physiological processes. In this Review, the author explains how, in cancer, each of these gaseous mediators exhibits a biphasic pharmacological character, whereby increasing or decreasing gasotransmitter concentrations in the tumour can exert antitumour effects.